Monitor the success of the offering given the best-efforts structure and no minimum. If the company fails to raise sufficient capital, it may face accelerated cash burn and potential delisting. Watch for Nasdaq compliance updates and any reverse stock split announcements.
Executive Summary
Aethlon Medical filed a pre-effective amendment to its S-1 for a best-efforts offering of up to 4,705,882 shares of common stock and warrants at $0.85 per unit, targeting ~$4M gross proceeds. The company is pre-revenue, has a going concern qualification, and trades below Nasdaq's $1.00 minimum bid price, creating delisting risk. The dilutive offering and lack of revenue make this a bearish event.
Key Financial Metrics
Key Facts
- Best-efforts offering of up to 4,705,882 shares of common stock and warrants at a combined price of $0.85 per share and warrant.
- Gross proceeds estimated at $4,000,000; net proceeds ~$3.335 million after fees and expenses.
- Company had $5 million in cash as of March 31, 2026, but has a going concern qualification and no revenue.
- Common stock closed at $0.85 on June 29, 2026, below Nasdaq's $1.00 minimum bid price for continued listing.
- Offering has no minimum; the company may raise substantially less than the maximum amount.
- Proceeds will be used for general corporate purposes including R&D, clinical trials, and working capital.
- Company has incurred significant operating losses and expects continued losses for the foreseeable future.
Financial Impact
Up to $4 million gross proceeds from the offering, with net proceeds of approximately $3.335 million after placement agent fees and expenses.
Risk Factors
- Best-efforts offering with no minimum may result in insufficient capital raised.
- Common stock is below Nasdaq's $1.00 minimum bid price, creating delisting risk.
- Going concern qualification raises substantial doubt about ability to continue operations.
- Immediate and substantial dilution for existing shareholders.
- Warrants require stockholder approval to become exercisable; failure to obtain approval would render them worthless.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001683168-26-005203 |
| Document: aethlon_ex1023.htm | 0001683168-26-005203 |
| Document: aethlon_ex0412.htm | 0001683168-26-005203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | SC 13G | $5.05 $5.07 | ▲ +0.40% | ▼ −0.06% | $5.07 (+0.40%) |
Oct 1, 2026 25d ago | 8-K | $6.45 $6.05 | ▲ +6.20% | ▲ +7.36% | $5.07 (+21.40%) |
Sep 17, 2026 5w ago | 425 | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.07 (−25.22%) |
Sep 17, 2026 5w ago | 8-K | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.07 (−25.22%) |
Sep 15, 2026 6w ago | 8-K | $1.47 $6.31 | ▲ +329.25% | ▲ +328.43% | $5.07 (+244.90%) |
Sep 4, 2026 7w ago | DEFA14A | $1.81 $1.47 | ▲ +18.78% | ▲ +17.67% | $5.07 (−180.11%) |
Aug 31, 2026 8w ago | 8-K | $2.06 $1.81 | ▼ −12.14% | ▼ −11.99% | $5.07 (+146.12%) |
Aug 13, 2026 10w ago | Press Release | $2.83 $2.73 | ▼ −3.53% | ▼ −2.17% | $5.07 (+79.15%) |
Jul 31, 2026 12w ago | 8-K | $0.6628 $0.6300 | ▲ +4.95% | ▲ +8.46% | $5.07 (−664.94%) |
Jul 7, 2026 16w ago | EFFECT | $0.7297 $0.6850 | ▲ +6.13% | ▲ +6.68% | $5.07 (−594.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers